Tirzepatide (Mounjaro) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for type 2 diabetes mellitus and chronic weight management
They focus on: Appetite regulation Muscle preservation Metabolic health Sustainable lifestyle habits That combination is the real reason GLP-1 weight loss plans work
Our team is dedicated to providing personalized treatments that fit seamlessly into your lifestyle
It covers in-vitro work and published laboratory-animal studies.It is not an injection, dosing, personal-use, household-use, medical, or veterinary guide
If you struggle to inject yourself, you can get someone to help but they must read the instructions for use first
While many patients successfully remain on 2.5 mg for longer than expected, there are situations where increasing the dose may be the right decision